Journal
CLINICAL BIOCHEMISTRY
Volume 45, Issue 10-11, Pages 727-732Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2012.04.013
Keywords
MicroRNA; Biomarker; Circulating; Acute myocardial infarction
Categories
Funding
- National Natural Science Foundation of China [30925018, 31130029, 81070559, 81100190]
- National Basic Research Program of China (973 Program) [2008CB517308, 2012CB517801]
- Natural Science Foundation Project of CQ CSTC (CSTC) [2009BA5044]
- National Center for Research Resources [P-20 RR-15581]
- National Heart, Lung, and Blood Institute [HL106256, HL63914]
- American Diabetes Association [07-8-IN-08]
- American Heart Association Western States Affiliate [11GRNT7610161]
Ask authors/readers for more resources
Coronary artery disease and acute myocardial infarction (AMI) are the leading causes of death for both men and women. Serum cardiac-specific troponin level is now used for the early diagnosis of AMI. However, due to the delayed release of troponin, an earlier, more sensitive and specific biomarker is urgently demanded to further reduce AMI mortality. Recent studies have found that circulating microRNAs (miRNAs) are closely linked to myocardial injury. Due to the cell-specific physiological functions and the stability of miRNAs in plasma, serum, and urine, they are emerging as sensitive biomarkers of AMI. This review summarizes the latest insights into the identification and potential application of plasma and serum miRNAs as novel biomarkers for diagnosis and prognosis of AMI. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
